Treatment outcome and prognostic molecular markers of supratentorial primitive neuroectodermal tumors

Seo Hee Choi, Se Hoon Kim, Kyu Won Shim, Jung Woo Han, Junjeong Choi, Dong Seok Kim, Chuhl Joo Lyu, Jun Won Kim, Chang Ok Suh, Jaeho Cho

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background To identify prognostic factors and define the optimal management of patients with supratentorial primitive neuroectodermal tumors (sPNETs), we investigated treatment outcomes and explored the prognostic value of specific molecular markers. Methods A total of 47 consecutive patients with pathologically confirmed sPNETs between May 1985 and June 2012 were included. Immunohistochemical analysis of LIN28, OLIG2, and Rad51 expression was performed and correlated with clinical outcome. Results With a median follow-up of 70 months, 5-year overall survival (OS) and progression-free survival (PFS) was 55.5% and 40%, respectively, for all patients. Age, surgical extent, and radiotherapy were significant prognostic factors for OS and PFS. Patients who received initially planned multimodal treatment without interruption (i.e., radiotherapy and surgery (subtotal resection), with or without chemotherapy) showed significantly higher 5-year OS (71.2%) and PFS (63.1%). In 29 patients with available tumor specimens, tumors with high expression of either LIN28 or OLIG2 or elevated level of Rad51 were significantly associated with poorer prognosis. Conclusions We found that multimodal treatment improved outcomes for sPNET patients, especially when radiotherapy and ≥subtotal resection were part of the treatment regimen. Furthermore, we confirmed the prognostic significance of LIN28 and OLIG2 and revealed the potential role of Rad51 in sPNETs.

Original languageEnglish
Article numbere0153443
JournalPloS one
Volume11
Issue number4
DOIs
Publication statusPublished - 2016 Apr

Fingerprint

Primitive Neuroectodermal Tumors
Tumors
neoplasms
genetic markers
Radiotherapy
radiotherapy
Disease-Free Survival
Combined Modality Therapy
resection
Survival
Chemotherapy
Surgery
prognosis
drug therapy
Neoplasms
surgery
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Choi, Seo Hee ; Kim, Se Hoon ; Shim, Kyu Won ; Han, Jung Woo ; Choi, Junjeong ; Kim, Dong Seok ; Lyu, Chuhl Joo ; Kim, Jun Won ; Suh, Chang Ok ; Cho, Jaeho. / Treatment outcome and prognostic molecular markers of supratentorial primitive neuroectodermal tumors. In: PloS one. 2016 ; Vol. 11, No. 4.
@article{3194cce72dfd441b8ac9525f233d4770,
title = "Treatment outcome and prognostic molecular markers of supratentorial primitive neuroectodermal tumors",
abstract = "Background To identify prognostic factors and define the optimal management of patients with supratentorial primitive neuroectodermal tumors (sPNETs), we investigated treatment outcomes and explored the prognostic value of specific molecular markers. Methods A total of 47 consecutive patients with pathologically confirmed sPNETs between May 1985 and June 2012 were included. Immunohistochemical analysis of LIN28, OLIG2, and Rad51 expression was performed and correlated with clinical outcome. Results With a median follow-up of 70 months, 5-year overall survival (OS) and progression-free survival (PFS) was 55.5{\%} and 40{\%}, respectively, for all patients. Age, surgical extent, and radiotherapy were significant prognostic factors for OS and PFS. Patients who received initially planned multimodal treatment without interruption (i.e., radiotherapy and surgery (subtotal resection), with or without chemotherapy) showed significantly higher 5-year OS (71.2{\%}) and PFS (63.1{\%}). In 29 patients with available tumor specimens, tumors with high expression of either LIN28 or OLIG2 or elevated level of Rad51 were significantly associated with poorer prognosis. Conclusions We found that multimodal treatment improved outcomes for sPNET patients, especially when radiotherapy and ≥subtotal resection were part of the treatment regimen. Furthermore, we confirmed the prognostic significance of LIN28 and OLIG2 and revealed the potential role of Rad51 in sPNETs.",
author = "Choi, {Seo Hee} and Kim, {Se Hoon} and Shim, {Kyu Won} and Han, {Jung Woo} and Junjeong Choi and Kim, {Dong Seok} and Lyu, {Chuhl Joo} and Kim, {Jun Won} and Suh, {Chang Ok} and Jaeho Cho",
year = "2016",
month = "4",
doi = "10.1371/journal.pone.0153443",
language = "English",
volume = "11",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

Treatment outcome and prognostic molecular markers of supratentorial primitive neuroectodermal tumors. / Choi, Seo Hee; Kim, Se Hoon; Shim, Kyu Won; Han, Jung Woo; Choi, Junjeong; Kim, Dong Seok; Lyu, Chuhl Joo; Kim, Jun Won; Suh, Chang Ok; Cho, Jaeho.

In: PloS one, Vol. 11, No. 4, e0153443, 04.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment outcome and prognostic molecular markers of supratentorial primitive neuroectodermal tumors

AU - Choi, Seo Hee

AU - Kim, Se Hoon

AU - Shim, Kyu Won

AU - Han, Jung Woo

AU - Choi, Junjeong

AU - Kim, Dong Seok

AU - Lyu, Chuhl Joo

AU - Kim, Jun Won

AU - Suh, Chang Ok

AU - Cho, Jaeho

PY - 2016/4

Y1 - 2016/4

N2 - Background To identify prognostic factors and define the optimal management of patients with supratentorial primitive neuroectodermal tumors (sPNETs), we investigated treatment outcomes and explored the prognostic value of specific molecular markers. Methods A total of 47 consecutive patients with pathologically confirmed sPNETs between May 1985 and June 2012 were included. Immunohistochemical analysis of LIN28, OLIG2, and Rad51 expression was performed and correlated with clinical outcome. Results With a median follow-up of 70 months, 5-year overall survival (OS) and progression-free survival (PFS) was 55.5% and 40%, respectively, for all patients. Age, surgical extent, and radiotherapy were significant prognostic factors for OS and PFS. Patients who received initially planned multimodal treatment without interruption (i.e., radiotherapy and surgery (subtotal resection), with or without chemotherapy) showed significantly higher 5-year OS (71.2%) and PFS (63.1%). In 29 patients with available tumor specimens, tumors with high expression of either LIN28 or OLIG2 or elevated level of Rad51 were significantly associated with poorer prognosis. Conclusions We found that multimodal treatment improved outcomes for sPNET patients, especially when radiotherapy and ≥subtotal resection were part of the treatment regimen. Furthermore, we confirmed the prognostic significance of LIN28 and OLIG2 and revealed the potential role of Rad51 in sPNETs.

AB - Background To identify prognostic factors and define the optimal management of patients with supratentorial primitive neuroectodermal tumors (sPNETs), we investigated treatment outcomes and explored the prognostic value of specific molecular markers. Methods A total of 47 consecutive patients with pathologically confirmed sPNETs between May 1985 and June 2012 were included. Immunohistochemical analysis of LIN28, OLIG2, and Rad51 expression was performed and correlated with clinical outcome. Results With a median follow-up of 70 months, 5-year overall survival (OS) and progression-free survival (PFS) was 55.5% and 40%, respectively, for all patients. Age, surgical extent, and radiotherapy were significant prognostic factors for OS and PFS. Patients who received initially planned multimodal treatment without interruption (i.e., radiotherapy and surgery (subtotal resection), with or without chemotherapy) showed significantly higher 5-year OS (71.2%) and PFS (63.1%). In 29 patients with available tumor specimens, tumors with high expression of either LIN28 or OLIG2 or elevated level of Rad51 were significantly associated with poorer prognosis. Conclusions We found that multimodal treatment improved outcomes for sPNET patients, especially when radiotherapy and ≥subtotal resection were part of the treatment regimen. Furthermore, we confirmed the prognostic significance of LIN28 and OLIG2 and revealed the potential role of Rad51 in sPNETs.

UR - http://www.scopus.com/inward/record.url?scp=84963604378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963604378&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0153443

DO - 10.1371/journal.pone.0153443

M3 - Article

C2 - 27074032

AN - SCOPUS:84963604378

VL - 11

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e0153443

ER -